insights_auto
Why is AXGN down 4,62%?
Dive Deeperchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
48,98 USD
arrow_downward
-4,62%(-2,37) 1D
5-ноя., 11:15:53 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
51,62 USD
High
51,85 USD
Low
48,95 USD
Mkt. cap
2,93 млд
Avg. vol.
1,78 млн
Volume
237,32 миң
52-wk high
52,91 USD
52-wk low
23,00 USD
EPS
-0,68 USD
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
Open
51,62 USD
High
51,85 USD
Low
48,95 USD
Mkt. cap
2,93 млд
Avg. vol.
1,78 млн
Volume
237,32 миң
52-wk high
52,91 USD
52-wk low
23,00 USD
EPS
-0,68 USD
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
News stories
From web sources and news partners
Investing.com
·
16 мүнөт мурун
Traders watch S&P 500 circuit-breaker levels as selloff deepens
Greater Milwaukee Today
·
20 мүнөт мурун
A wipeout for AI stocks sends Wall Street tumbling, and the S&P 500 drops more than 3%
marketscreener.com
·
1 саат мурун
S&P 500 futures steady after midterm rally; Nasdaq lags on chip weakness
www.tmgm.com
·
2 күн мурун
Apple's margin forecast sends Dow Jones Industrial Average lower
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersАлачуа, Флорида, Америка Кошмо Штаттары
SectorMedical device
Industry-
Websiteaxogeninc.com